These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7585113)

  • 41. Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors-In Silico Activity Prediction.
    Dąbrowska A; Pieńko T; Taciak P; Wiktorska K; Chilmonczyk Z; Mazurek AP; Stasiulewicz A
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV-protease inhibitors.
    Flexner C
    N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584
    [No Abstract]   [Full Text] [Related]  

  • 44. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
    Campiani G; Nacci V; Fiorini I; De Filippis MP; Garofalo A; Greco G; Novellino E; Altamura S; Di Renzo L
    J Med Chem; 1996 Jul; 39(14):2672-80. PubMed ID: 8709096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 46. Analysis of resistance mutants of viral polymerases.
    Oxford JS; al-Jabri AA; Stein CA; Levantis P
    Methods Enzymol; 1996; 275():555-600. PubMed ID: 9026659
    [No Abstract]   [Full Text] [Related]  

  • 47. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.
    D'Aquila RT
    Clin Lab Med; 1994 Jun; 14(2):393-422. PubMed ID: 7523021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting HIV-1 protease: a test of drug-design methodologies.
    West ML; Fairlie DP
    Trends Pharmacol Sci; 1995 Feb; 16(2):67-75. PubMed ID: 7762084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase.
    Althaus IW; Chou KC; Lemay RJ; Franks KM; Deibel MR; Kezdy FJ; Resnick L; Busso ME; So AG; Downey KM; Romero DL; Thomas RC; Aristoff PA; Tarpley WG; Reusser F
    Biochem Pharmacol; 1996 Mar; 51(6):743-50. PubMed ID: 8602869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase.
    Bartolucci C; Cellai L; Marzano M; Segre A; Brufani M; Filocamo L; Bianco AD; Guiso M; Brizzi V; Benedetto A
    Farmaco; 1995 Sep; 50(9):587-93. PubMed ID: 7495468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
    J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).
    Sandström E; Oberg B
    Drugs; 1993 Apr; 45(4):488-508. PubMed ID: 7684670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protease inhibitors and prevention of cross resistance.
    Levin J
    AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M; Clotet B; Martínez MA
    J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.
    Shan Y; Ma Y; Wang M; Dong Y
    Curr Med Chem; 2012; 19(34):5885-94. PubMed ID: 22963668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
    McCarrick MA; Kollman P
    Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
    [No Abstract]   [Full Text] [Related]  

  • 58. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
    Kilby JM; Saag MS
    Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
    Smerdon SJ; Jäger J; Wang J; Kohlstaedt LA; Chirino AJ; Friedman JM; Rice PA; Steitz TA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3911-5. PubMed ID: 7513427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives.
    Burlet S; Pietrancosta N; Laras Y; Garino C; Quéléver G; Kraus JL
    Curr Pharm Des; 2005; 11(24):3077-90. PubMed ID: 16178746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.